Morningstar
•
Oct 30, 2026
Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals Earnings: Strong Growth and Pipeline Progress
Summary
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Technical Assessment: Bullish in the Intermediate-Term
Nov 02, 2026
•
CVX, TEVA
Analyst Report: Sanofi
Nov 02, 2026
•
SNY
Analyst Report: AstraZeneca PLC
Nov 02, 2026
•
AZN
Analyst Report: AbbVie Inc.
Nov 02, 2026
•
ABBV
Analyst Report: Illumina, Inc.
Oct 30, 2026
•
ILMN
